NCT03173417View on ClinicalTrials.gov

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

May 23, 2017

Primary Completion Date

May 1, 2019

Study Completion Date

May 1, 2019

Conditions
Leukemia
Interventions
BIOLOGICAL

IM19 CAR-T

T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

DRUG

fludarabine and cyclophosphamide

Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days

Trial Locations (1)

Unknown

Hebei Yanda Ludaopei Hospital, Beijing

All Listed Sponsors
lead

Beijing Immunochina Medical Science & Technology Co., Ltd.

INDUSTRY

NCT03173417 - Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T) | Biotech Hunter | Biotech Hunter